FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, in particular to biologically active peptides having anti-inflammatory properties due to the ability to inhibit migration of monocytic blood cells, stimulated by protein MCP-1 (monocyte chemoattractant protein-1). Declared is 13-member peptide of formula KWVQDSINYLNKK-Y, where Y=NH2, having anti-inflammatory additional antioxidant and antiaggregatory properties, or its pharmaceutically acceptable salts.
EFFECT: said compounds can be used in treating diseases associated with migration of monocytes and requiring prolonged therapy, such as atherosclerosis, psoriasis, rheumatoid arthritis, dermatitis, and so forth.
1 cl, 1 tbl, 3 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD OF ASSESSING THE EFFICIENCY OF ANTI-CLEGGANT MEDICINAL PRODUCT IN WHOLE PERIPHERAL BLOOD SAMPLES | 2022 |
|
RU2800671C1 |
RGD-LIKE PEPTIDES | 2009 |
|
RU2396271C1 |
PEPTIDE FOR INHIBITING FRACTALKINE-STIMULATED MIGRATION OF MONOCYTIC CELLS | 2011 |
|
RU2461565C1 |
THROMBOCYTE AGGREGATION-INHIBITING HETEROMERIC PEPTIDES BASED ON IMIDAZO[4,5-e]BENZO[1,2-c;3,4-c']DIFUROXANE | 2014 |
|
RU2550223C1 |
PEPTIDE ELICITING CAPACITY TO INHIBIT MIGRATION OF MONOCYTIC CELLS STIMULATED BY PROTEIN MCP-1 | 2003 |
|
RU2260598C2 |
THROMBOCYTE AGGREGATION-INHIBITING N-CARB(GLUTAMINYL)OXYMETHYLIMIDAZO[4,5-E]BENZO[1,2-C;3,4-C']DIFUROXANE | 2012 |
|
RU2502739C9 |
METHOD FOR FUNCTIONAL AND QUANTITATIVE EVALUATION OF PLATELET-MONOCYTIC COMPLEXES IN WHOLE PERIPHERAL BLOOD SAMPLES | 2020 |
|
RU2762820C1 |
THROMBOCYTE AGGREGATION-INHIBITING N-CARB(ARGINYL)OXYMETHYLIMIDAZO[4,5-e]BENZO[1,2-c;3,4-c']DIFUROXANE | 2014 |
|
RU2549355C1 |
METHOD FOR THE PRODUCTION OF PLATELETS BY A METHOD FOR ROTATIONAL MIXING OF THE CULTURE | 2016 |
|
RU2756000C2 |
PHARMACEUTICAL COMPOSITION WITH PROLONGED RELEASE OF DODECAPEPTIDE INGRAMON | 2022 |
|
RU2793124C1 |
Authors
Dates
2024-10-01—Published
2022-06-02—Filed